PierianDx will commercialise diagnostic tools for personalised medicine.
Washington University is spinning out PierianDx, set up to commercialise research in genomic technology that will offer diagnostic tools for personalised medicine. The genomic technology is based on research by geneticists and medical practitioners at the St Louis institution.
The spin-out will commercialise the technology as part of a system – dubbed Clinical Genomicist Workstation – developed in the medical labs at the university. That system has been used at Washington since 2011, and sequences a patient’s DNA to determine…
